1. Describe the role of eosinophils and type 2 inflammation in severe asthma and eosinophil-associated diseases.
2. Identify the mechanisms of action of biologic therapies for severe asthma and eosinophil-associated diseases.
3. Distinguish severe asthma and related eosinophilic diseases from one another using clinical presentation, diagnostic test results, and input from subspecialty consultants. 4. Apply the results of clinical studies that examine the tolerability, efficacy, and safety of approved agents when selecting and monitoring therapy for severe asthma and associated eosinophilic diseases.
Learning Objectives
Epidemiology of Severe Asthma • About 5-15% of asthma patients have severe disease, not controlled by available therapies.
• This group accounts for > 50% of health care utilization related to asthma and is at increased risk of asthma-related death.
"Severe" Asthma 
Conclusions
• Asthma is a spectrum of diseases, with different pathologic and clinical phenotypes • There has been an increased understanding of the immunology of asthma, leading to new therapeutic options • Defining phenotypes/endotypes in asthma is a young field, but it is making progress. • In the severe asthma population Investigating and managing comorbidities cannot be overemphasized • Tailoring treatment to phenotypes/endotypes and/or treatable traits is the ultimate goal.
